KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Short term Debt (2017 - 2025)

Historic Short term Debt for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $7.2 million.

  • Amneal Pharmaceuticals' Short term Debt fell 9679.47% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 9679.47%. This contributed to the annual value of $224.2 million for FY2024, which is 2525.87% up from last year.
  • Amneal Pharmaceuticals' Short term Debt amounted to $7.2 million in Q3 2025, which was down 9679.47% from $290.0 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Short term Debt registered a high of $290.0 million during Q1 2025, and its lowest value of $7.2 million during Q3 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' median Short term Debt value was $85.0 million (recorded in 2022), while the average stood at $120.7 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Short term Debt skyrocketed by 22762.18% in 2023 and then plummeted by 9679.47% in 2025.
  • Amneal Pharmaceuticals' Short term Debt (Quarter) stood at $47.9 million in 2021, then rose by 25.36% to $60.0 million in 2022, then soared by 198.33% to $179.0 million in 2023, then increased by 25.26% to $224.2 million in 2024, then plummeted by 96.79% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $290.0 million for Q2 2025, and $290.0 million during Q1 2025.